Back to News
Market Impact: 0.4
Roche's Lunsumio Shows Improved OS And PFS In Comparative Study For Follicular Lymphoma
Source: Nasdaq
Healthcare & BiotechProduct Launches
Roche announced that its Phase 3 CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. The positive late-stage result supports the potential expansion of Roche's lymphoma treatment portfolio, although the article provides no efficacy magnitude, safety data, or regulatory timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- Waymo to launch robotaxis in Singapore, its first Southeast Asia market, by 2028
- Waymo to bring autonomous ride-hailing to Singapore in 2028
- Waymo says Singapore will be its next international robotaxi city
- Halozyme prices $1.3 billion convertible notes offering
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A